CD33 and acute myeloid leukemia: Furthermore, a high frequency of BM-associated CD11b+ CD33+ HLA−DR− MDSC-like blasts is associated with a significantly shorter overall survival and poor prognosis, whereas a low number of MDSC-like blasts may indicate leukemia-free survival of AML patients.